What is Glycotest?
Glycotest Diagnostics operates at the intersection of biotechnology and oncology, focusing on the development of non-invasive blood-based assays for the early detection of liver cancer and fibrosis-cirrhosis. By leveraging algorithm-driven biomarker panels, the company addresses a significant unmet need in global healthcare, particularly for patients suffering from chronic conditions like viral hepatitis and metabolic liver disease. Their technology represents a shift toward precision diagnostics, aiming to replace more invasive procedures with streamlined, data-backed blood analysis that improves clinical outcomes and patient accessibility.
How much funding has Glycotest raised?
Glycotest has raised a total of $13.2M across 2 funding rounds:
Series A
$10M
Stock/Share Issuance
$3.2M
Series A (2018): $10M with participation from Shanghai Fosun Pharmaceutical Co. , Ltd. and Fosun Pharmaceutical Co.
Stock/Share Issuance (2026): $3.2M, investors not publicly disclosed
Key Investors in Glycotest
Shanghai Fosun Pharmaceutical Co., Ltd.
A global healthcare group and pharmaceutical leader focused on R&D, manufacturing, and the commercialization of innovative medical products.
Fosun Pharmaceutical Co.
A major investment entity specializing in the life sciences sector, providing strategic capital to companies developing breakthrough diagnostic and therapeutic solutions.
Undisclosed Investor
An institutional partner participating in the latest funding round to support the continued development of non-invasive diagnostic technologies.
What's next for Glycotest?
With the recent infusion of capital, Glycotest is well-positioned to accelerate its clinical validation programs and expand its commercial footprint. The strategic focus will likely shift toward integrating these biomarker panels into standard clinical workflows, thereby enhancing the diagnostic accuracy for high-risk populations. As the company matures, the emphasis will remain on scaling its proprietary assay infrastructure to meet the rising global demand for early-stage cancer detection, potentially setting the stage for further enterprise-level partnerships or market expansion in the diagnostic space.
See full Glycotest company page
